

FY 1995 ALLOTMENT—ADMINISTRATION ON DEVELOPMENTAL DISABILITIES—Continued

	Basic support	Protection and advocacy
Indiana	1,302,452	744,977
Iowa	675,944	386,552
Kansas	542,948	310,561
Kentucky	1,033,459	590,954
Louisiana	1,192,757	682,120
Maine	350,000	257,000
Maryland	856,778	490,112
Massachusetts	1,134,143	648,518
Michigan	2,156,605	1,233,228
Minnesota	911,599	521,451
Mississippi	808,637	462,472
Missouri	1,180,512	675,168
Montana	350,000	257,000
Nebraska	351,445	257,000
Nevada	350,000	257,000
New Hampshire	350,000	257,000
New Jersey	1,300,902	743,905
New Mexico	398,477	257,000
New York	3,543,800	2,026,261
North Carolina	1,618,418	925,698
North Dakota	350,000	257,000
Ohio	2,558,401	1,463,137
Oklahoma	764,811	437,566
Oregon	622,209	356,003
Pennsylvania	2,691,147	1,538,848
Rhode Island	350,000	257,000
South Carolina	928,228	530,930
South Dakota	350,000	257,000
Tennessee	1,264,751	723,305
Texas	3,653,197	2,090,445
Utah	441,518	271,831
Vermont	350,000	257,000
Virginia	1,266,674	724,506
Washington	955,540	546,737
West Virginia	611,379	349,473
Wisconsin	1,154,768	660,402
Wyoming	350,000	257,000
American Samoa	200,000	137,495
Guam	200,000	137,495
Marshall Islands ¹	200,000	0
Micronesia ¹	200,000	0
Palau ¹	200,000	0
Puerto Rico	1,569,650	918,335
Trust Territories ²	0	137,495
Virgin Islands	200,000	137,495
Northern Mariana Islands	200,000	137,495

¹The 1990 Amendments to the Developmental Disabilities Assistance and Bill of Rights Act (the Act) provided that the Republic of the Marshall Islands, the Federated States of Micronesia and the Republic of Palau (formerly the Trust Territories of the Pacific Islands (TTPI)) each would receive a minimum allotment under the Basic Support formula program.

²Prior to the Act, TTPI had been eligible for a single minimum allotment under both programs, Basic Support and Protection and Advocacy. Under the 1990 Amendments, TTPI continues to be eligible for a single minimum amount under the Protection and Advocacy program; however, under the Compact of Free Association, P. L. 99-239, only the Republic of Palau continues to be eligible to receive funds under the Protection and Advocacy program. Therefore, the Republic of Palau will receive its proportional share of the TTPI allotment, and the remainder will be withheld for reallocation in accordance with section 142(b)(1) of the Act.

Dated: March 11, 1994.

Bob Williams,

Commissioner, Administration on
Developmental Disabilities.

[FR Doc. 94-7347 Filed 3-28-94; 8:45 am]

BILLING CODE 4184-01-P

Agency for Toxic Substances and Disease Registry

[ATSDR-419]

Public Health Interventions To Prevent or Mitigate Possible Adverse Health Effects Related to the Bunker Hill Superfund Site Hazardous Exposures

SUMMARY: The Agency for Toxic Substances and Disease Registry (ATSDR) announces the availability of fiscal year (FY) 1994 funds for a grant

with the Idaho Department of Health and Welfare (IDHW) to provide public health interventions for individuals and community members living near the Bunker Hill Superfund site to prevent or mitigate possible adverse health effects related to exposure to lead and other hazardous substances. Approximately \$50,000 is available in FY 1994 to fund this project. It is expected that the award will begin on or about May 15, 1994, for a 12-month budget period, within a five year project period.

Funding estimates may vary and are subject to change. Continuation awards within the project period will be made on the basis of satisfactory progress and the availability of funds.

The purpose of this project is for ATSDR to assist the Idaho Department of Health and Welfare (IDHW) to: (1) Develop, disseminate and evaluate appropriate educational programs and materials to educate community members and health professionals about the health effects related to exposure to lead and other hazardous substances; (2) Coordinate and refer cases of exposure for appropriate health follow-up interventions related to blood lead screening activities in the Silver Valley; and (3) Provide counseling to citizens who have concerns and questions about the health effects of lead exposure.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to the priority area of Environmental Health and Health Promotion. (For ordering a copy of Healthy People 2000, see the section **WHERE TO OBTAIN ADDITIONAL INFORMATION.**)

Authority: This program is authorized under Sections 104 (i) (1)(E), (4), (14), and (15) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA), as amended by the Superfund Amendments and Reauthorization Act of 1986 (SARA) [42 U.S.C. 9604 (i) (1)(E), (4), (14), and (15)].

Smoke-Free Workplace

The PHS strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American People.

Eligible Applicant

Assistance will be provided only to the Idaho Department of Health and Welfare (IDHW). No other applications will be solicited. The program announcement and application kit have been sent to IDHW. The IDHW has developed a unique expertise participating in health studies and health intervention programs in Silver Valley, Shoshone County, Idaho. The IDHW and Panhandle Health District have a legislated mandate to provide health services to residents of the Silver Valley area.

The IDHW has a history of working with ATSDR and the CDC to determine

adverse health effects related to lead exposure from the Bunker Hill Superfund site. Studies conducted by IDHW funded by the CDC and more recently the ATSDR have documented an unacceptable level of lead absorption among children who live near the Bunker Hill lead smelter in northern Idaho. ATSDR is concerned about the health of children, pregnant women and other populations at risk living near the Bunker Hill Superfund site because of existing lead exposure and possible new lead exposures from soil and dust during remediation of the site by the Environmental Protection Agency. ATSDR has determined that there is a need for communitywide preventive interventions related to lead exposure for individuals and community members living near the Bunker Hill Superfund site.

Executive Order 12372 Review

The application is subject to Intergovernmental Review of Federal Programs as governed by Executive Order (E.O.) 12372. E.O. 12372 sets up a system for State and local government review of proposed Federal assistance applications. The applicant should contact their Single Point of Contact (SPOC) as early as possible to alert them to the prospective application and receive any necessary instructions on the State process. Information on the Idaho SPOC is included in the application kit sent to the applicant. If the SPOC has any State process recommendations on applications submitted to CDC, they should forward them to Henry S. Cassell, Grants Management Officer, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Atlanta, Georgia 30305, no later than 60 days after the application deadline date. The granting agency does not guarantee to "accommodate or explain" for State process recommendations it receives after that date.

Public Health System Reporting Requirements

This program is not subject to the Public Health System Reporting Requirements.

Catalog of Federal Domestic Assistance Number

The Catalog of Federal Domestic Assistance number is 93.161.

Where To Obtain Additional Information

If you are interested in obtaining additional information regarding this

project, please refer to Announcement Number 419 and contact Ms. Maggie Slay, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 321, Mailstop E-13, Atlanta, Georgia 30305, (404) 842-6797.

A copy of Healthy People 2000 (Full Report, Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report, Stock No. 017-001-00473-1) referenced in the SUMMARY may be obtained through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone (202) 783-3238.

Dated: March 23, 1994.

Walter R. Dowdle,

Deputy Administrator, Agency for Toxic Substances and Disease Registry.

[FR Doc. 94-7317 Filed 3-28-94; 8:45 am]

BILLING CODE 4163-70-P

Food and Drug Administration

[Docket No. 94N-0014]

General Electric Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the General Electric Co., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of *p*-cumylphenol as a chain terminator in the manufacture of polycarbonate resins intended for use in food-contact applications.

DATES: Written comments on the petitioner's environmental assessment by April 28, 1994.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-254-9500.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 4B4413) has been filed by the General Electric Co., 1 Lexan Lane, Mt. Vernon, IN 47620-9364. The petition proposes to amend the food additive regulations in § 177.1580

Polycarbonate resins (21 CFR 177.1580) to provide for the safe use of *p*-cumylphenol as a chain terminator in the manufacture of polycarbonate resins intended for use in food-contact applications.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before April 28, 1994, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: February 28, 1994.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 94-7249 Filed 3-28-94; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 94N-0113]

Drug Export; NEUTROLITE® Kit for the Preparation of Technetium TC99m Bicisate

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the Du Pont Merck Pharmaceutical Co. has filed an application requesting approval for the export of the human drug NEUTROLITE® kit for the preparation of technetium TC99m bicisate to Denmark.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug Evaluation and Research (HFD-313), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2073.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that the Du Pont Merck Pharmaceutical Co., 331 Treble Cove Rd., North Billerica, MA 01862, has filed an application requesting approval for the export of the human drug NEUTROLITE® kit for the preparation of technetium TC99m bicisate to Denmark. This product is indicated for the evaluation of regional cerebral perfusion abnormalities in adult patients with central nervous system disorders. The application was received and filed in the Center for Drug Evaluation and Research on February 2, 1994, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by April 8,

1994, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and Research (21 CFR 5.44).

Dated: March 17, 1994.

Raymond E. Hamilton,

Acting Director, Office of Compliance, Center for Drug Evaluation and Research.

[FR Doc. 94-7342 Filed 3-28-94; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 94N-0112]

Drug Export; PHOTOLEX Plus™ Broad Spectrum Sunscreen Lotion

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Allergan Herbert, Division of Allergan, Inc., has filed an application requesting approval for the export of the human drug PHOTOLEX Plus™ Broad Spectrum Sunscreen Lotion to Canada.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION

CONTACT: James E. Hamilton, Center for Drug Evaluation and Research (HFD-313), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857; 301-594-2073.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency